Achieving ‘Marginal Gains’ to Optimise Outcomes in Resectable Pancreatic Cancer
Open Access
Abstract
Improving outcomes among patients with resectable pancreatic cancer is one of the greatest challenges of modern medicine. Major improvements in survival will result from the development of novel therapies. However, optimising existing pathways, so that patients realise benefits of already proven treatments, presents a clear opportunity to improve outcomes in the short term. This narrative review will focus on treatments and interventions where there is a clear evidence base to improve outcomes in pancreatic cancer, and where there is also evidence of variation and under-treatment. Avoidance of preoperative biliary drainage, treatment of pancreatic exocrine insufficiency, prehabiliation and enhanced recovery after surgery, reducing perioperative complications, optimising opportunities for elderly patients to receive therapy, optimising adjuvant chemotherapy and regular surveillance after surgery are some of the strategies discussed. Each treatment or pathway change represents an opportunity for marginal gain. Accumulation of marginal gains can result in considerable benefit to patients. Given that these interventions already have evidence base, they can be realised quickly and economically.Keywords
This publication has 206 references indexed in Scilit:
- Randomised clinical trial: a 1‐week, double‐blind, placebo‐controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1‐year open‐label extensionAlimentary Pharmacology & Therapeutics, 2013
- The Daily Practice of Pancreatic Enzyme Replacement Therapy After Pancreatic Surgery: a Northern European SurveyJournal of Gastrointestinal Surgery, 2012
- Screening older cancer patients: first evaluation of the G-8 geriatric screening toolAnnals of Oncology, 2012
- Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant TherapyJournal of the American College of Surgeons, 2012
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment StrategiesCell, 2012
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- Resection Benefits Older Adults with Locoregional Pancreatic Cancer Despite Greater Short‐Term Morbidity and MortalityJournal of the American Geriatrics Society, 2011
- EORTC elderly task force position paper: Approach to the older cancer patientEuropean Journal of Cancer, 2010
- Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DR ainage vs. (direct) OP eration (DROP-trial)BMC Surgery, 2007
- Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts: Figure 1Gut, 2006